License vs Non-Assertion: A Subtle but Critical Distinction in Patent Transactions

13 May 2026

By Royal Hu

In intellectual property agreements, it is common to see the patent holder of a certain technology promise not to assert infringement against the other party regarding this patent in the future.

The clause was labeled “Non-Assertion.” In intellectual property practice, many would instead call this a “Covenant Not to Sue” (CNS).

The terms have different names but similar legal attributes.

But here’s the catch:

although non-assertion commitments and licenses may look commercially similar, they are fundamentally different in legal structure, and that difference can have significant consequences for risk allocation, supply chain protection, and litigation strategy.

Two Structures, Two Logics

At the heart of the distinction is a simple question: What exactly is the patent owner giving up (or giving away)?

1. License: A Grant of Rights

A patent license is, at its core, an affirmative grant.

The patent owner transfers part of its exclusive rights (such as the right to make, use, or sell) to the licensee. This creates a legal entitlement. If a dispute arises, the (technology user) licensee’s position is straightforward: “I am allowed to do this.”

This matters. A license does not merely reduce risk: it creates a legal basis for conduct.

2. Covenant Not to Sue: A Promise of Restraint

A CNS or non-assertion clause works very differently.

It does not grant any rights. Instead, it is a contractual limitation on enforcement. The patent owner is not saying the conduct is lawful: only that it will not take action against it.

In litigation, the technology user’ s defense shifts accordingly: “You agreed not to sue me.”

This may sound like a subtle distinction, but in practice it changes everything.

Why Use a CNS Instead of a License?

If licenses are stronger, why do parties sometimes choose CNS structures?

Because flexibility and strategy often outweigh formal rights.

1. Avoiding Heavy Licensing Frameworks

A full license often comes with complexity:

scope definitions
sublicensing rights
royalty structures
audit mechanisms

A CNS, by contrast, can be a lighter, faster solution, especially when parties want to resolve a specific issue without building a long-term relationship.

2. Precision in Scope Control

CNS arrangements are inherently personal and targeted.

A patent owner may agree:

not to sue you (or the company)
but reserve rights against your affiliates, suppliers, or customers

This level of selective tolerance can also be achieved in licensing, but typically at the cost of more complicated structuring.

3. Litigation Strategy (Especially in the U.S.)

In U.S. patent litigation, CNS can be a powerful procedural tool.

If an alleged infringer files a declaratory judgment action (seeking a ruling of non-infringement or invalidity), the patent owner may issue a sufficiently broad CNS to eliminate the “case or controversy.” Without that, the court may lose jurisdiction, effectively ending the case.

This makes CNS not just a business tool, but also a litigation exit strategy.

The Risks Behind the Flexibility

That flexibility comes at a cost. CNS structures can create hidden vulnerabilities, particularly in cross-border and supply chain contexts.

1. Weakness Against Third Parties

A CNS binds the promising party, not the patent itself.

If the patent is later transferred, especially to an aggressive enforcement entity, the new owner may argue: “The previous owner promised not to sue you. I didn’t.”

Without a formal license, the counterparty may find itself exposed again.

Practical takeaway: CNS agreements should always include successor-binding clauses, ensuring that future assignees are contractually tied to the same non-assertion commitment.

2. Patent Exhaustion: A Hidden Battlefield

One of the most sensitive issues is how CNS interacts with patent exhaustion.

Under this principle, once a product is sold with the patent owner’s authorization, the patent rights over that product are exhausted, meaning no further claims can be made downstream.

Some patent owners attempt to use CNS structures to argue:

the sale was merely “tolerated,” not “authorized”
therefore, exhaustion should not apply

However, in Impression Products v. Lexmark, the U.S. Supreme Court emphasized a more substantive approach: What matters is whether the sale was authorized in reality, not how the agreement is labeled.

In other words, if a CNS effectively allows products to enter the market, it may still trigger exhaustion.

That said, how CNS is interpreted varies across jurisdictions and fact patterns, leaving room for uncertainty, particularly in international supply chains.

When CNS Makes Sense

Despite the risks, CNS is far from a “weaker license.” It is a deliberate strategic tool, often used in the following scenarios:

• Dispute Settlement

Resolving past infringement by agreeing not to pursue claims for specific products or activities.

• Technology Collaboration

In joint development or supply relationships where parties want to avoid full cross-licensing but still manage risk within a defined project scope.

• Transitional Business Arrangements

Providing interim protection while patent applications are pending or negotiations are ongoing.

• Ecosystem Building

Encouraging industry adoption of a technology through public non-assertion commitments (as seen in certain open innovation models).

• Litigation Management

Strategically terminating disputes by removing the legal basis for court jurisdiction.

A Practical Way to Think About It

The difference between a license and a CNS is not about terminology: it is about legal architecture.

A license answers: → “Do you have the right to do this?”
A CNS answers: → “Will I enforce my rights against you?”

These are not interchangeable questions.

Final Thoughts

For businesses operating across China and international markets, this distinction is more than academic.

If you are the user of technology, a license generally provides stronger, more durable protection, especially against future patent transfers.
If you are the patent owner, a CNS offers flexibility, allowing you to resolve disputes or enable cooperation while preserving broader enforcement leverage.

In a world where patents increasingly intersect with complex supply chains, data-driven technologies, and cross-border enforcement, choosing between these two tools is a strategic decision.

And sometimes, the smallest clause in a contract carries the biggest implications.

Cover Photo by Jose Castillo on Unsplash